BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abraxane nab-paclitaxel: Additional Phase III data

Additional data from an open-label, international Phase III trial in 1,052 patients showed that first-line Abraxane plus carboplatin missed the secondary endpoint of significantly increasing PFS vs. paclitaxel plus carboplatin. Abraxis BioScience Inc. previously reported that Abraxane plus carboplatin met...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >